Breckenridge Pharmaceutical Initiates Class II Recall of Duloxetine Due to Nitrosamine Impurity
Breckenridge Pharmaceutical, Inc. has initiated a U.S. nationwide Class II recall for 1,829 bottles of Duloxetine Delayed-Release Capsules, 60mg. The recall, D-0552-2025, stems from Current Good Manufacturing Practices (CGMP) deviations, specifically the presence of N-nitroso-duloxetine impurity exceeding safety limits. This event mandates immediate action for procurement and regulatory teams managing generic antidepressant supply chains.
FDA-Mandated Class II Recall for Breckenridge Pharmaceutical's Duloxetine
Breckenridge Pharmaceutical, Inc., based in Berkeley Heights, NJ, has initiated a Class II recall (D-0552-2025) for specific lots of Duloxetine Delayed-Release Capsules, USP, 60mg. This U.S. nationwide recall, which commenced on July 15, 2025, impacts 1,829 60-count bottles from Lot 230836C, with an expiration date of February 28, 2026. The affected product carries the NDC 51991-748-10. It is crucial for procurement directors to note that while Breckenridge Pharmaceutical, Inc. is the distributor, the product was manufactured by Towa Pharmaceutical Europe, S.L. in Martorelles, Barcelona, Spain. This distinction is vital for understanding the origin of the quality deviation. For supply chain VPs, this means immediate action is required to identify and quarantine any affected stock within their distribution networks. The Class II classification signifies that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote, necessitating prompt removal from the market to protect patient safety and maintain product integrity across the supply chain.
Commercial Impact of N-nitroso-duloxetine Impurity and CGMP Deviations
The fundamental reason for this recall is identified as "CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit." This finding directly impacts the commercial viability and regulatory standing of the recalled Duloxetine product. N-nitroso-duloxetine is a nitrosamine impurity, a class of compounds that has been under intense scrutiny by global regulatory bodies due to potential carcinogenic risks. Exceeding established safety assessment limits for such impurities indicates a significant lapse in Current Good Manufacturing Practices (CGMP) at the manufacturing site, Towa Pharmaceutical Europe, S.L. For regulatory affairs heads, this highlights the critical need for robust impurity control strategies and rigorous quality assurance protocols throughout the entire product lifecycle, from API sourcing to finished product release. Business development executives must consider the potential reputational damage associated with such a recall, which can erode trust among healthcare providers and patients, potentially impacting future market share for generic Duloxetine products distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Towa Pharmaceutical Europe, S.L.
Mitigating Supply Chain Disruptions for Generic Duloxetine
This recall of Duloxetine Delayed-Release Capsules, a widely used generic antidepressant, presents an immediate challenge for procurement directors and supply chain VPs. The identification of a nitrosamine impurity originating from a European manufacturer underscores the necessity of comprehensive supplier qualification and ongoing monitoring, regardless of geographic location. Procurement teams must immediately audit their existing inventory of Duloxetine, specifically checking for the affected lot distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Towa Pharmaceutical Europe, S.L. Furthermore, it is imperative to review quality agreements and certificates of analysis for all generic Duloxetine suppliers to ensure that nitrosamine testing and control measures are adequately addressed. For organizations reliant on Breckenridge Pharmaceutical, Inc. for their Duloxetine supply, this event necessitates an urgent assessment of alternative sourcing strategies to prevent potential stockouts or supply chain vulnerabilities. Diversifying suppliers and understanding the complete manufacturing provenance of critical generic drugs are paramount to maintaining continuity of supply and mitigating future recall-related disruptions.
Evolving Regulatory Landscape for Nitrosamine Control in Pharmaceuticals
The presence of N-nitroso-duloxetine impurity in Breckenridge Pharmaceutical's recalled product is not an isolated incident but reflects a broader, intensified regulatory focus on nitrosamine control within the pharmaceutical industry. Regulatory bodies globally, including the FDA, have been issuing guidance and enforcing stricter limits on these impurities across various drug classes for several years. This ongoing scrutiny means that regulatory affairs heads must proactively implement comprehensive nitrosamine risk assessments for all active pharmaceutical ingredients (APIs) and finished drug products, not just those currently under recall. This includes evaluating potential sources of nitrosamine formation during synthesis, manufacturing, and storage, as well as establishing robust analytical testing methods to detect and quantify these impurities. For business development executives, understanding this evolving regulatory landscape is critical for product development and market entry strategies, as compliance with stringent impurity limits is now a non-negotiable aspect of bringing new generic drugs to market and maintaining existing product portfolios. Proactive engagement with these regulatory expectations is essential to avoid future compliance issues and costly recalls.